CaRLO — Cancer Research Library Online

1

Unknown

Histopathological findings in intracerebral hemorrhage (2011)

Holling, M ; Jeibmann, A ; Fischer, BR ; [et al.]

German Medical Science GMS Publishing House; Düsseldorf

In: 62. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgen (PNCH); 20110507-20110511; Hamburg; DOCDI.05.02 /20110428/

add to mindlist on the mindlist

Details

Publication Date: 2011-04-28

Keywords: ddc: 610

Language: English

Type: conferenceObject

Permalink

Signatur	Availability

Others were also interested in ...

GERMAN MEDICAL SCIENCE

Fulltext

2

Unknown

Frontal skull base (pseudo-)mucocele - delayed complications after head injuries (2007)

Fischer, B ; Jeibmann, A ; Wassmann, H ; [et al.]

German Medical Science GMS Publishing House; Düsseldorf

In: 58. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC); 20070426-20070429; Leipzig; DOCFR.08.03 /20070411/

add to mindlist on the mindlist

Details

Publication Date: 2007-04-04

Keywords: skull base ; (pseudo-)mucocele ; head injury ; Schädel-Basis ; (Pseudo-)Mukozele ; Schädelhirntrauma ; ddc: 610

Language: English

Type: conferenceObject

Permalink

Signatur	Availability

Others were also interested in ...

GERMAN MEDICAL SCIENCE

Fulltext

3

Unknown

ADAMTS-genes and risk of cerebral aneurysm (2015)

Arning, A ; Jeibmann, A ; Köhnemann, S ; [et al.]

German Medical Science GMS Publishing House; Düsseldorf

In: 66. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC); 20150607-20150610; Karlsruhe; DOCP 141 /20150602/

add to mindlist on the mindlist

Details

Publication Date: 2015-06-03

Keywords: Aneurysm ; Genes ; ADAMTS ; ddc: 610

Language: English

Type: conferenceObject

Permalink

Signatur	Availability

Others were also interested in ...

GERMAN MEDICAL SCIENCE

Fulltext

4

Unknown

Myopericytoma: a series of 5 cases impacting on the nervous system (2013)

Holling, M ; Jeibmann, A ; Paulus, W ; [et al.]

German Medical Science GMS Publishing House; Düsseldorf

In: 64. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC); 20130526-20130529; Düsseldorf; DOCP 135 /20130521/

add to mindlist on the mindlist

Details

Publication Date: 2013-05-22

Keywords: Myopericytoma ; Tumoren ; ddc: 610

Language: English

Type: conferenceObject

Permalink

Signatur	Availability

Others were also interested in ...

GERMAN MEDICAL SCIENCE

Fulltext

5

Unknown

BRAF V600E immunohistochemistry in the diagnosis of Pleomorphic xanthoastrocyomas and Gangliogliomas (2012)

Kölsche, C ; Schittenhelm, J ; Wöhrer, A ; [et al.]

German Medical Science GMS Publishing House; Düsseldorf

In: 57th Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN); 20120912-20120915; Erlangen; DOC12dgnnPP3.30 /20120911/

add to mindlist on the mindlist

Details

Publication Date: 2012-09-12

Keywords: ddc: 610

Language: English

Type: conferenceObject

Permalink

Signatur	Availability

Others were also interested in ...

GERMAN MEDICAL SCIENCE

Fulltext

6

Unknown

Vasospasm after SAH mediated by the acute phase protein MRP14 - a pilot study (2010)

Fischer, B ; Holling, M ; Jeibmann, A ; [et al.]

German Medical Science GMS Publishing House; Düsseldorf

In: 61. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC) im Rahmen der Neurowoche 2010; 20100921-20100925; Mannheim; DOCP1853 /20100916/

add to mindlist on the mindlist

Details

Publication Date: 2010-09-17

Keywords: ddc: 610

Language: English

Type: conferenceObject

Permalink

Signatur	Availability

Others were also interested in ...

GERMAN MEDICAL SCIENCE

Fulltext

7

Unknown

From glioblastoma to gangliocytoma - a peculiar pediatric path? (2009)

Holling, M ; Jeibmann, A ; Brentrup, A ; [et al.]

German Medical Science GMS Publishing House; Düsseldorf

In: 60. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit den Benelux-Ländern und Bulgarien; 20090524-20090527; Münster; DOCP12-05 /20090520/

add to mindlist on the mindlist

Details

Publication Date: 2009-06-30

Keywords: ddc: 610

Language: English

Type: conferenceObject

Permalink

Signatur	Availability

Others were also interested in ...

GERMAN MEDICAL SCIENCE

Fulltext

8

Unknown

Somatostatin receptor subtype 2 (sst) is a potential prognostic marker and a therapeutic target in medulloblastoma

Remke M ; Hering E ; Gerber NU ; [et al.]

Childs Nervous System 29 (8), 1253-1262

add to mindlist on the mindlist

Details

Keywords: CANCER ; DIAGNOSIS ; GENE-EXPRESSION ; MUTATIONS ; CENTRAL-NERVOUS-SYSTEM ; CHILDREN ; DIFFERENTIAL EXPRESSION ; NEUROENDOCRINE TUMORS ; EARLY-CHILDHOOD MEDULLOBLASTOMA ; POSTOPERATIVE CHEMOTHERAPY

Abstract: INTRODUCTION: Neuroectodermal tumors in general demonstrate high and dense expression of the somatostatin receptor subtype 2 (sst2). It controls proliferation of both normal and neoplastic cells. sst2 has thus been suggested as a therapeutic target and prognostic marker for certain malignancies. METHODS: To assess global expression patterns of sst 2 mRNA, we evaluated normal (n = 353) and tumor tissues (n = 340) derived from previously published gene expression profiling studies. These analyses demonstrated specific upregulation of sst 2 mRNA in medulloblastoma (p 〈 0.001). sst2 protein was investigated by immunohistochemistry in two independent cohorts. RESULTS: Correlation of sst2 protein expression with clinicopathological variables revealed significantly higher levels in medulloblastoma (p 〈 0.05) compared with CNS-PNET, ependymoma, or pilocytic astrocytoma. The non-SHH medulloblastoma subgroup tumors showed particularly high expression of sst2, when compared to other tumors and normal tissues. Furthermore, we detected a significant survival benefit in children with tumors exhibiting high sst2 expression (p = 0.02) in this screening set. A similar trend was observed in a validation cohort including 240 independent medulloblastoma samples. CONCLUSION: sst2 is highly expressed in medulloblastoma and deserves further evaluation in the setting of prospective trials, given its potential utility as a prognostic marker and a therapeutic target.

DOI: 10.1007/s00381-013-2142-4

Type of Publication: Journal article published

PubMed ID: 23677175

Deep Link: http://www.dkfz.de/cgi-bin/sel?http://www.dkfz.de/PublicationManager/Show/ShowJournal.aspx%3fpublishedId=41013

Permalink

Signatur	Availability

Others were also interested in ...

DKFZ PUBLICATION

9

Unknown

Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups

Thomas,C. ; Sill,M. ; Ruland,V. ; [et al.]

Neuro-Oncology 18 (6), 790-796

add to mindlist on the mindlist

Details

Type of Publication: Journal article published

PubMed ID: 26826203

Deep Link: http://www.dkfz.de/cgi-bin/sel?http://www.dkfz.de/PublicationManager/Show/ShowJournal.aspx%3fpublishedId=69271

Permalink

Signatur	Availability

Others were also interested in ...

DKFZ PUBLICATION

10

Unknown

Cribriform neuroepithelial tumor (crinet): Molecular characterization of a smarcb1-deficient non-rhabdoid tumor with favorable long-term outcome

Johann PD ; Hovestadt V ; Thomas C ; [et al.]

Brain Pathology 27 (4), 411-418

add to mindlist on the mindlist

Details

Abstract: Rhabdoid phenotype and loss of SMARCB1 expression in a brain tumor are characteristic features of atypical teratoid/rhabdoid tumors (ATRT). Rare non-rhabdoid brain tumors showing cribriform growth pattern and SMARCB1 loss have been designated cribriform neuroepithelial tumor (CRINET). Small case series suggest that CRINETs may have a relatively favorable prognosis. However, the long-term outcome is unclear and it remains uncertain whether CRINET represents a distinct entity or a variant of ATRT. Therefore, 10 CRINETs were clinically and molecularly characterized and compared with 10 ATRTs of each of three recently described molecular subgroups (i.e. ATRT-TYR, ATRT-SHH and ATRT-MYC) using Illumina Infinium HumanMethylation450 arrays, FISH, MLPA, and sequencing. Furthermore, outcome was compared to a larger cohort of 27 children with ATRT-TYR. Median age of the 6 boys and 4 girls harboring a CRINET was 20 months (range 10-129 months). On histopathological examination, all CRINETs demonstrated a cribriform growth pattern and distinct tyrosinase staining. On unsupervised cluster analysis of methylation data, all CRINETs examined exclusively clustered within the ATRT-TYR molecular subgroup. As ATRT-TYR, CRINETs mainly showed large heterozygous 22q deletions (9/10) and SMARCB1 mutations of the other allele. In two patients, SMARCB1 mutations were also present in the germline. Estimated mean overall survival in patients with CRINETs was 125 months (95% confidence interval 100-151 months) as compared to only 53 (33-74) months in patients with ATRTs of the ATRT-TYR subgroup (Log-Rank P〈0.05). In conclusion, CRINET represents a SMARCB1-deficient non-rhabdoid tumor, which shares molecular similarities with the ATRT-TYR subgroup but has distinct histopathological features and favorable long-term outcome. This article is protected by copyright. All rights reserved.

Type of Publication: Journal article published

PubMed ID: 27380723

Deep Link: http://www.dkfz.de/cgi-bin/sel?http://www.dkfz.de/PublicationManager/Show/ShowJournal.aspx%3fpublishedId=70822

Permalink

Signatur	Availability

Others were also interested in ...

DKFZ PUBLICATION